Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF
| Autor: | Gloria Kayani, Saverio Virdone, Jean-Pierre Bassand, Ajay K. Kakkar, Garfield-Af Investigators, Giuseppe Ambrosio, Ramon Corbalan, A. John Camm, Erberto Carluccio, Lorenzo G. Mantovani |
|---|---|
| Přispěvatelé: | Ambrosio, G, Bassand, J, Corbalan, R, Kayani, G, Carluccio, E, Mantovani, L, Virdone, S, Kakkar, A, Camm, A |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system Heart failure 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Risk Factors Original Research Articles Internal medicine Heart rate medicine Humans GARFIELD‐AF Original Research Article 030212 general & internal medicine Stroke Fibrillation business.industry Hazard ratio Anticoagulant Anticoagulants Atrial fibrillation medicine.disease Blood pressure lcsh:RC666-701 Cardiology medicine.symptom GARFIELD-AF Cardiology and Cardiovascular Medicine business Kidney disease |
| Zdroj: | ESC Heart Failure, Vol 8, Iss 2, Pp 1139-1149 (2021) ESC Heart Failure |
| ISSN: | 2055-5822 |
| Popis: | Aims: Heart failure (HF) and atrial fibrillation (AF) may coexist and influence each other. However, characteristics, anticoagulant treatment, and outcomes of contemporary AF patients with concurrent HF are ill-defined. This study analyses characteristics, treatment, and 2year outcomes in newly diagnosed Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) patients with vs. without HF. Methods and results: GARFIELD-AF is the world's largest observational AF patient study. At enrolment, 11758 of 52072 patients (22.6%) had HF; 76.3% were New York Heart Association class II–III. Patients with HF had comparable demographics, blood pressure, and heart rate but more likely had permanent (15.6% vs. 11.9%) or persistent AF (18.9% vs. 13.8%), acute coronary syndromes (16.7% vs. 8.9%), vascular disease (40.8% vs. 20.2%), and moderate-to-severe chronic kidney disease (14.6% vs. 9.0%) than those without. Anticoagulant prescription was similar between the two groups. At 2year follow-up, patients with HF showed a greater risk of all-cause mortality [hazard ratio (HR), 2.06; 95% confidence interval (CI), 1.91–2.21; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text